NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

Evaluation of Progression in Multiple Sclerosis by Magnetic Resonance Imaging (MRI)

This study is currently recruiting participants.

Summary | Eligibility | Citations | Contacts

Summary

Number

89-N-0045

Sponsoring Institute

National Institute of Neurological Disorders and Stroke (NINDS)

Recruitment Detail

Type: Participants currently recruited/enrolled
Gender: Male & Female
Min Age: 18 Years
Max Age: 120 Years

Referral Letter Required

No

Population Exclusion(s)

Children

Keywords

Multiple Sclerosis;
MRI (Magnetic Resonance Imaging);
Natural History

Recruitment Keyword(s)

None

Condition(s)

Multiple Sclerosis

Investigational Drug(s)

None

Investigational Device(s)

None

Intervention(s)

None

Supporting Site

National Institute of Neurological Disorders and Stroke

Studies performed under 89-N-0045 are designed to examine the natural history of multiple sclerosis (MS) using MRI and immunological measures. In addition to studying the natural history of untreated patients, the natural history of patients receiving approved disease-modifying therapies of MS will be examined. In both cohorts of patients levels of disease activity on MRI will be compared with immunological characteristics in order to help identify disease mechanism. Patients with either definite MS (based either on clinical or combined clinical and MRI criteria) or with an initial presentation of neurological dysfunction consistent with MS will be studied longitudinally by MRI. Disease activity on MRI will be assessed using several MRI measures of disease activity including the number of contrast enhancing lesions, the overall burden of disease, brain atrophy and measures to assess axonal damage. Patients will be assessed clinically and correlations between immunological and genetic factors and disease activity as seen clinically or by MRI will be studied.

A second cohort of patients starting the use of approved therapy will also be examined. Patients referred to NIH prior to beginning approved therapy will be assessed with a series of three monthly MRIs to determine the level of pretreatment disease activity. After beginning approved therapy under the direction of their private physician, patients will be followed similarly to the natural history cohort. Immunological and genetic findings will be accessed before and during therapy in order to help establish the mechanisms of action of the therapies and to identify mechanisms accounting for either a response or lack of response to therapy. Part of the collected samples willl be cryopreserved to provide respository for further studies focusing on detection of biomarkers indicative of disease state, disease stage or repsonse to therapies.

Additionally, a cohort of normal volunteers will be studied. The studies in the normal volunteers will be used to establish the most appropriate imaging sequences for studying normal white matter in MS patients using magnetization transfer (MT) imaging sequences for studying normal white matter in MS patients using magnetization transfer (MT) imaging and to provide normative immunological measures.

--Back to Top--

Eligibility

INCLUSION CRITERIA:

-One of the following:

--Diagnosis of MS or clinically isolated syndrome based on currently accepted diagnostic criteria.

--Presentation with neuroimaging features consistent with MS.

--Diagnosis of another disease of the CNS

--Healthy volunteer.

-Age greater than or equal to 18.

-Able to give informed consent.

NIH employees are eligible to participate.

EXCLUSION CRITERIA:

-Contraindication to MRI.

-Pregnancy.

-Unwilling to allow coded samples to be processed offsite or unwilling to have coded samples used in other studies.


--Back to Top--

Citations:

Clinical safety of serial monthly administrations of gadopentetate dimeglumine in patients with multiple sclerosis: implications for natural history and early-phase treatment trials

Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI

Increases insoluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b

--Back to Top--

Contacts:

Principal Investigator

Referral Contact

For more information:

Daniel S. Reich, M.D.
National Institute of Neurological Disorders and Stroke (NINDS)
NIHBC 10 - CLINICAL CENTER BG RM 5C103
10 CENTER DR
BETHESDA MD 20892
(301) 496-1801
reichds@ninds.nih.gov

Jenifer E. Dwyer
National Institute of Neurological Disorders and Stroke (NINDS)
National Institutes of Health
Building 10
Room 5C429
10 Center Drive
Bethesda, Maryland 20892
(301) 496-3825
jenifer.dwyer@nih.gov

Office of Patient Recruitment
National Institutes of Health Clinical Center (CC)
Building 61, 10 Cloister Court
Bethesda, Maryland 20892
Toll Free: 1-800-411-1222
Local Phone: 301-451-4383
TTY: TTY Users Dial 7-1-1
ccopr@nih.gov

Clinical Trials Number:

NCT00001248

--Back to Top--